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The assessment of breast cancer morphology remains an important element in the evaluation of prognosis and therapeutic planning
for this disease. The tumour morphology reflects the molecular profile that produced it and consequently each can be predictive of
the other.
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The morphological attributes of a breast cancer, as assessed by
histological examination, supply the breast cancer care team with
invaluable prognostic and predictive information. Notwithstand-
ing the great advances in molecular techniques available to study
such tumours, morphology remains indispensable. Studies of most
large cohorts of unselected breast cancers continue to show that
grade, nodal status and tumour size remain the most powerful
prognostic indicates in a multivariable analysis. It is these that are
combined in the Nottingham Prognostic Index, the most widely
used prognostic tool in use in the UK (Balslev et al, 1994). This is
not to suggest that molecular events are not important, but
morphology, the visual consequence of a chaotic interplay of
multiple molecular alterations is readily analysed and interpreted.
Interestingly, in order to comprehend the results of some cDNA
array work, analysis has involved the elaboration of complex
diagnostic representations of data – a neomorphological approach
that surely reinvents the wheel.
Tumour size and nodal status are very much temporal factors,
whereas grade is very much a morphological attribute and is
qualitative. In other words, grade is a reflection of the intrinsic
qualities of a tumour and as a consequence, will give an indication
of features such as to the rapidity of growth and probability of
metastasis. In this review, I will concentrate on the relationship of
the morphological attributes of breast cancer to underlying
molecular events and give examples of how these relate both to
long-established taxonomic categories, and to some emerging
ones. I will also examine their relationship to predictive markers
and to specific biological peculiarities. By molecular techniques, I
will, elastically, also encompass some cytogenetic alterations.
DIVERSITY IN BREAST CANCER
Breast cancer is an extraordinarily diverse group of diseases in
terms of presentation, morphology and molecular profile. Since
the behaviour and response of these tumours to treatment is also
equally disparate, linking these is a worthwhile, but not trivial,
task. Established breast cancer taxonomy divides breast cancers
into tumours of special type, of which tubular, mucinous,
medullary and lobular carcinomas are examples, and ductal
carcinoma of no special type (NST) (Ellis et al, 1992). This
classification is predicated on the recognition of a feature or suite
of features that contribute to a distinctive appearance (special type
tumours), or lack of these (tumours of NST). It is worth saying that
the classic split between ‘lobular’ and ‘ductal’ ‘carcinoma’ was
based on belief that there were distinct microanatomical origins
for these tumours; however, the current view is that most breast
cancers arise from the terminal duct lobular unit (Wellings et al,
1975). The broad difference between these two groups emanates
from their differing molecular profiles. Ductal carcinomas of NST
represent the largest group of tumours and contains a diverse
group of lesions within which distinct, covert types undoubtedly
exist; however, it is the special type tumours that show the most
well-documented morphology/molecular profile/behavioural rela-
tionships.
LOBULAR CARCINOMA
Lobular carcinoma shows distinctive clinical features with
metastases within coelomic cavities and to odd sites more common
than in other tumour types (Harris et al, 1984; Dixon et al, 1991;
du Toit et al, 1991). This tumour also presents a distinctive
morphological picture whose key elements include growth of cells
in narrow cords – Indian files, a swirling pattern around benign
breast tissue, the ‘targetoid pattern’, often a diffuse growth, skip
lesions whereby satellite of tumour are seen separated from the
main lesion by uninvolved benign tissue and cellular discohesion.
Despite this, ‘a precise definition of lobular carcinoma remains
elusive’ (Di Costanzo et al, 1990). Of the listed features, the
discohesion now appears pivotal, since there is inactivation of the
E-cadherin gene, either though a truncation mutation (Berx et al,
1995, 1996) in approximately 50% (Berx et al, 1996), or
methylation of its promoter (Droufakou et al, 2001). E-cadherin
is one of the main genes concerned with cell–cell interaction and
the elaboration of polarity in epithelial cells. Via interactions with
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influence cell morphology and motility (Bracke et al, 1997;
Handschuh et al, 1999). The number of lobular carcinomas
showing E-cadherin mutations varies between studies and no
doubt reflects pathologist behaviour; diagnosis historically has
been made utilising the full suite of features detailed above, but
awareness that E-cadherin inactivation as a major molecular altera-
tion with consequent cellular discohesion may have influenced
more recent diagnostic behaviour.
MORPHOLOGICAL DIVERSITY IN LOBULAR
CARCINOMAS
Casual observation reveals that even so-called classic pattern
lobular carcinomas show morphological variation; however, the
molecular correlations for this variety remain uncharted. Some of
the more distinct, but rare, variant types do manifest molecular
and behavioural differences. In general, these tumours are more
aggressive (Dixon et al, 1982). Some exhibit features of apocrine
differentiation (Eusebi et al, 1984), which has also been termed the
histiocytoid variant because of the resemblance of these cells to
histiocytes. Some examples of the pleomorphic variant, which for
some may also encompass some tumours with apocrine features
(Eusebi et al, 1992), show attributes more in common with high-
grade ductal carcinomas, such as a more diverse cytogenetic
alterations (see below). There are also therapeutic consequences,
and unlike in classical pattern lobular carcinomas, HER2
amplification often occurs.
MUCINOUS CARCINOMA
These lesions are characterised by tumour cells resting in pools of
mucin with manifest as empty spaces disrupting the tissue. It is the
type of mucin that these lesions produce that may account, in part,
for the distinctive morphology. Benign mammary epithelium and
many breast cancers produce transmembrane mucins, mainly
from the MUC1 gene (Taylor-papadimitrou et al, 2002). In
mucinous carcinomas, there is a switch to the production of gel-
forming mucins, products of the MUC2 and MUC5 genes
(O’Connell et al, 1998). It is easy to see how this could cause the
tissue disruption and facilitate the distinct morphology of these
lesions. One may speculate that both the volume of mucin
contributing to overestimation of tumour size and early detection
and the possibility that the ensheathing mucin might hinder the
entrance of tumour cells into the vasculature, could contribute to
the very good prognosis typical of these tumours. The survival
figures of these lesions approaches the age-matched population –
as long as they are wholly mucinous without any elements of
ductal carcinoma NST, that is, they are ‘pure’ (Fentiman et al,
1997). It is therefore of interest to note that ‘impure’ elements –
such as components of ductal carcinoma NST revert or continue to
elaborate MUC1 mucins (O’Connell et al, 1998) and tumours
exhibiting this do less well.
The mucin profile has other potential therapeutic ramifications;
in many breast cancers, the glycosylation of the MUC-1 mucin side
chains is altered and the mucin variant presents a potential target
for immunotherapy (Taylor-papadimitrou et al, 2002); however,
this is not an option for mucinous carcinomas which do not
produce MUC-1.
The changes in MUC gene expression are also seen in a
spectrum of coexistent changes from mucinous DCIS at the
malignant end of the spectrum through to the benign mucocele-
like lesions and mucin-filled ducts – implying a field change
(O’Connell et al, 1998). Since this mucin may take up calcium,
there has been increased detection of benign ‘mucinous’ lesions
(Carder and Liston, 2003) leading to some difficult problems for
the Breast Screening Team.
Molecular explanations for some associations with mucinous
lesions remain elusive; for example, the association of some
mucinous carcinomas with neuroendocrine differentiation (Capella
et al, 1980) and the occurrences of mucinous/lobular mixed lesions
(Gad and Azzopardi, 1975).
OTHER SPECIAL TYPE CARCINOMAS
Included within the special type subgroup are a number of low-
grade lesions such as tubular and mucinous carcinomas. Tubular
carcinomas typically share the classic 16q/1q change seen in grade
I and lobular tumours (see below) and like lobular carcinomas can
be multifocal. As yet, no specific defining abnormalities have been
revealed for these tumours. The regular loss of 16q in these and
other breast tumours implies the presence of relevant tumour-
suppressor gene(s) on 16q; although various tumour-suppressor
genes have been implicated, for example CTCF (Filipopva et al,
1998), none have been proven as pathogenic.
The rest of the special types group includes two generally higher
grade types of lesions – metaplastic and medullary carcinoma –
both of which will be discussed more later, and a number of rarer
lesions. Of the latter groups, adenoid-cystic and adenosquamous
carcinomas are notable.
MIXED DUCTAL AND LOBULAR CARCINOMAS
Classic lobular carcinoma and grade I ductal tumours show broad
similarities at the cytogenetic level. Cohorts of both tumour types
exhibit relatively few changes, when compared with grade III
tumours and commonly show loss of at least some of the
chromosome arm 16q and gain of 1p; the former including the
E-cadherin locus. This suggests that these morphologically
dissimilar lesions may be closely related. Mixed ductal and lobular
elements in breast cancers are not uncommon and where these
morphologies are intermingled, variable methylation of the E-
cadherin promoter seems a more plausible explanation for the
patchy morphology and E-cadherin expression in these hybrid
lesions, than E-cadherin gene mutation (Graff et al, 2000). These
findings imply that some lobular and ductal carcinomas are very
similar and in some cases represent parts of the same lesion.
However, this story is not always so straightforward – some grade I
tumours can appear E-cadherin negative by immunohistochem-
istry and yet form tubular structures – implying a degree of
functional redundancy for E-cadherin, with other cadherins
accounting for the necessary cell–cell cohesion (Tan et al, 1999).
Note that in the UK, it is necessary to meet certain criteria
percentages for the different components for the category ‘mixed’
as a practical expedient dictated by the National Health Service
Breast Screening Programme (NHSBSP), but these rules under-
estimate the number of lesions that have some element of mixed
morphology.
GRADE AND TUMOURS OF NST
Grade has been mentioned several times already. In breast disease
it has a specific meaning and is derived using methodology evolved
from that documented in a seminal paper by Bloom and
Richardson (1957), devised by Scarfe, a pathologist. As originally
described, there were inherent imprecisions, and the modified
methodology described by Elston and Ellis (1991) is the one that is
generally used today. Tumours are given a cumulative score based
on the assessment of tubule formation, pleomorphism and mitotic
activity, which then allows division into grade I (least ‘aggressive’),
through to III (most ‘aggressive’). The term ‘grade’ taken at face
value could imply a continuum of biological behaviour with
progression between grades – so-called ‘phenotypic drift’. This
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although the boundaries between the grade groups are arbitary,
tumours tend not to evolve through grade (Blamey, 1993; Johnson
and Shekhdar, 2001). Morphological studies comparing recurrence
and metastasis with primary lesions support this view and more
recently cytogenetic studies (Roylance et al, 1999). Cytogenetic
studies of Pan-grade groups both show evidence of intratumoural
heterogeneity (Aubele et al, 1999) and disparate findings between
breast cancers with a wide range of changes across the
chromosome spreads. In unselected cohorts, no clear pattern
emerges since either the cohorts had not been chosen to fully
represent all grades or the element of grade had not been included
at all. Roylance and co-workers, however, examined the relation-
ship of grade I ductal carcinoma to grade III tumours. The results
revealed distinct differences between the two groups; grade I
tumours showed a relatively narrow spread of changes notably
with loss of 16q (65%) and gain of 1q(70%) being dominant. In
grade III lesions, the changes were more diverse. AlThough there
were some commoner changes, for example, amplification of 17q
corresponding, none was as frequent as the 16q/1q gain seen in
grade I lesions. Furthermore, while 16q loss did occur in the grade
III group (16%), this was qualitatively different (Roylance et al,
2002). These results support the view that, in general, grade I
tumours are unlikely to evolve to grade III tumours, which is also
supported by further evidence discounting the implausibility of
regain of genetic material on 16q in grade III lesions. Curiously, as
detailed above, they are more cytogenetically similar to the
morphologically dissimilar lobular carcinomas. To crystallize –
grade I ductal tumours encompass different types to grade III
tumours and these observations give reasonable justification for
‘within grade’ research.
GRADING IDIOSYNCRASY
Confusingly, for the non-initiated grading runs in parallel with the
taxonomic system that divides breast carcinomas into ductal
carcinomas of NST, lobular carcinomas and several varieties of
special type carcinomas. Additionally, the several classifications
used for Ductal carcinoma in situ also use the term ‘grade’, but
generally refer only to the nuclear characterisic of the noninvading
malignant cells of this precursor lesion (Douglas-Jones et al, 1996),
whereas modified Bloom and Richardson grading is derived from a
composite of nuclear pleomorphism, tubule formation and mitotic
activity. This explains why it is possible to have a grade I tumour
arising from high-grade DCIS.
HIGH-GRADE TUMOURS: MORE DIVERSITY
Even within the high-grade group of tumours, behavioural
diversity in terms of disease progression, survival and response
to therapy is high. This is matched by morphological and
molecular heterogeneity within this group. There are however
some distinct molecular markers which both internally divide this
tumour group and also, in some cases, help explain distinctive
biology and morphology.
HER2 AMPLIFIED TUMOURS
As well as predicting for response to Herceptin, HER2 amplifica-
tion is interesting with regards to morphological correlations.
These tumours are associated with a poor prognosis which is,
however, not independent of grade. HER2-amplified tumours are
typically high grade and show increased mitotic activity, a high
degree of nuclear pleomorphism and an association with comedo
necrosis (Berger et al, 1988; Borg et al, 1989, 1991) in associated
DCIS. One of the most notable is the observation that up to 91% of
Paget’s disease of the nipple shows this phenomenon (Lammie
et al, 1989). In vitro studies may explain this; amplication of HER2
in breast cell lines causes them to become epidermotropic
(Schelfhout et al, 2000). Another notable observation is that while
60% of pure DCIS in one study exhibited evidence of HER2 gene
amplification, this dropped to 25% of with infiltrating ductal
carcinoma, co-existent with the difference between in situ and
invasive being even more marked when high nuclear grade lesions
were matched (Barnes et al, 1992). Furthermore, HER2-amplified
DCIS is often very extensive. Taken together, the latter two
observations imply that HER2-amplified breast cancer may have a
prolonged in situ phase allowing widespread duct colonisation
before invasion. They also suggest that there is a population of
other, different, high-grade breast cancers with a short in situ
phase prior to invasion.
BRCA-RELATED TUMOURS
BRCA1-related tumours can have distinct morphological features,
similar, if not identical, to ‘medullary’ carcinoma (Eisinger et al,
1998). Medullary carcinoma is interesting on many levels and has
both the attributes of a special type cancer and a high-grade lesion.
Reproducibility of diagnosis is problematic (Gaffey et al, 1995) and
many, including myself avoid using the term, since the good
prognosis related to this lesion in the original work has been
difficult to reproduce in subsequent series. A notable feature of
BRCA-1-related tumours is the possession of high mitotic rates
(Armes et al, 1999), particularly if the mutation is at the 50 end
(Breast-Cancer-Linkage-Consortium, 1997). Correlating LOH of
the BRCA-1 locus to morphology in a study of sporadic tumours
also showed an association with extremely high mitotic counts –
occasionally exceeding 100 per 10 high power fields. HER2
amplification is extremely rare in tumours associated with
germline mutations of BRCA-1, which correlates well with the
absent or sparse amounts of DCIS typically seen.
For tumours associated with germline mutation of BRCA-2, an
association with lobular carcinomas (Armes et al, 1999) has been
suggested but since then no firm morphological correlation has
been proven.
METAPLASTIC CARCINOMAS
This group of tumours show a wide variety of patterns but are
linked by the propensity of the neoplastic population to take on
the characteristics of a cell presumed to be other than the
originating type. As a consequence, squamous cell carcinomas of
the breast are encompassed in this group. However, the majority
show the phenomenon of epithelial–mesenchymal transformation
(EMT), whereby the epithelium switches to a mesenchymal
phenotype (Gilles and Thompson, 1996). This may produce a
nonspecific sarcomatous appearace, or even produce a tumour
exhibiting features indicative of specific mesenchymal differentia-
tion – such as osteosarcomatous differentiation. A number of
generic changes such as downregulation of E-cadherin, keratin
profile alterations and upregulation of vimentin occur in the EMT
seen in these lesions (Gilles and Thompson, 1996; Fuchs et al,
2002) and, as such, mirror the changes of EMT which necessarily
occur during embryonic development.
Metaplastic carcinomas have been divided into five groups and
for one of these, matrix-producing carcinoma, MIC-2 upregulation
has been claimed as distinctive (Milanezi et al, 2001) in a small
series of lesions; it remains to be seen as to whether this will hold
true when larger cohorts are studied. What is emerging, however,
is the view that many of these lesions show evidence of basal/
myoepithelial differentiation (Oberman, 1987; Wargotz et al, 1989;
Foshini and Eusebi, 1998).
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BREAST CANCERS
As above, at least some metaplastic carcinomas have features
indicative of basal/myoepithelial differentiation, unlike most
breast cancers that exhibit features of the inner, luminal cells
of the breast. Initial studies of tumours with distinctive
morphological features, notably large, acellular central zones,
which ‘resemble burnt ruins after a forest fire’ (Tsuda et al,
1999), showed that these too often had basal/myoepithelial
features. These tumours showed a relatively poor outcome in
comparison to other breast carcinomas (Tsuda et al, 2000). These
findings were also associated with distinct morphology with
spindle cells, central fibrosis and necrosis and very high mitotic
rate more common (Tsuda et al, 2000). Finally, attention to the
metastatic patterns of the tumours in this cohort support the view
that these cancers are a distinct tumour type; metastasis is less
common, but when it does occur, it happens more quickly and
more often goes to the brain and lungs than other breast cancers
(Tsuda et al, 2000).
DO MORPHOLOGICAL OBSERVATIONS MATTER AND
WHAT DOES THE FUTURE HOLD?
There is no doubt that interobserver variability make morphology an
imprecise tool (Cserni, 1999; Dunne and Going, 2001), but there is
no evidence so far that any combination of molecular attributes can
be used to predict the morphological, behavioural and drug response
profiles of all breast cancers. Certainly array-based studies have
shown distinct expression patterns related to drug response and to
survival data, but as yet do not supplant morphology in routine use.
Many of the distinct morphologies described have known distinct
molecular attributes; if it looks different, it probably is different.
Recognition of distinct lesions is important to factor into the study
of breast cancer biology, in particular the design of study cohorts
and trial analysis since they may present distinct molecular targets
and/or response profiles. It may be that forms of molecular profiling
techniques will ultimately replace morphological analysis in tumour
classification (Bell, 1999; Alizadeh et al, 2001), but for now this
morphology continues to make an important contribution to the
investigation of the diverse group of diseases we call breast cancer.
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